Methodologies used to identify and characterize interactions among antiepileptic drugs

Expert Review of Clinical Pharmacology

Volumn 5, Issue 3, 2012, Pages 281-292

  Johannessen Landmark, Cecilie ^a   Patsalos, Philip N ^b,c  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

Author keywords

antiepileptic drugs; clinical studies; cytochrome P450; enzyme induction; enzyme inhibition; pharmacodynamic interactions; pharmacokinetic interactions; population pharmacokinetic modeling; preclinical studies; seizure models; therapeutic drug monitoring; uridine glucuronyl transferases

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DEOXYGLUCOSE; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; GABAPENTIN; GANAXOLONE; HARKOSERIDE; HUPERZINE A; ICA 105665; LAMOTRIGINE; NXA 5055; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

AREA UNDER THE CURVE; CEREBROSPINAL FLUID; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENZYME INDUCTION; EPILEPSY; GENE FREQUENCY; GENE PRODUCT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARMACOGENETICS; POST HOC ANALYSIS; REVIEW; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; URINARY EXCRETION;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; MODELS, ANIMAL; SEIZURES;

EID: 84861424237     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.10     Document Type: Review

References (85)

1. Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of antiepileptic drugs at a referral center for epilepsy. Seizure 16, 356-364 (2007).
2. Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of patients with epilepsy in a nation-wide population. Epilepsy Res. 95, 51-59 (2011).
3. Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand. 113, 405-411 (2006); erratum in: Acta Neurol. Scand. 114, 70 (2006).
4. Johnell K, Fastbom J. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nation-wide study of over 1,300,000 older people. Eur. J. Clin. Pharmacol. 67(10), 1069-1075 (2011).
5. Halvorsen KH, Granas AG, Engeland A, Ruthe S. Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiol. Drug Saf. doi:10.1002/pds.2232 (2011) (Epub ahead of print).
6. Brodie MJ, Sills GJ. Combining antiepileptic drugs-rational polytherapy? Seizure 20(5), 369-375 (2011).
7. Deckers CL, Czuczwar SJ, Hekster YA et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41, 1364-1374 (2000).
8. Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 48, 412-434 (2007).
9. Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 50, 387-397 (2009).
10. Luszczki JJ, Andres-Mach MM, Ratnaraj N, Patsalos PN, Czuczwar SJ. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48, 806-815 (2007).
11. Luszczki JJ, Andres MM, Czuczwar P et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 47, 10-20 (2006).
12. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol. 595, 13-21 (2008).
13. Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterizations of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse electroshock-induced seizure model. Naunyn Schmiedebergs Pharmacol. 379(2), 163-179 (2009).
14. Luszczki JJ, Filip D, Florek-Luszcki M. Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. Epilepsy Res. 98(2-3), 148-156 (2012).
15. Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, Gergont A, Kroczka S, Kacinski M. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin. Drug Metab. Toxicol. 5, 131-136 (2009).
16. Luszcki JJ, Trojanr MK, Ratanaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res. 90(3), 188-198 (2010).
17. Rowan AJ, Meijer JW, de Beer-Pawlikowski N, van der Geest P, Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 40(13), 797-802 (1983).
18. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40, 1141-1146 (1999).
19. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 342, 185-186 (1993).
20. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 61, 246-255 (2006).
21. Besag FM, Berry DJ, Pool F, Boyd SG, Berry D, Neville BG. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 39(2), 183-187 (1998).
22. Sake JK, Hebert D, Isojarvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24, 1055-1068 (2010).
23. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347-356 (2003).
24. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2, 473-481 (2003).
25. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second-and third-generation antiepileptic drugs. Expert Rev. Neurother. 10(1), 119-140 (2010).
26. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106(1), 97-132 (2005).
27. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics 6(1), 16-21 (2006).
28. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit. 29, 687-710 (2007).
29. Seo T, Nagata R, Ishitsu T et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics 9(5), 527-537 (2008).
30. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic1 Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of antiepileptic drugs at a referral center for epilepsy. Seizure 16, 356-364 (2007).
31. Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab. Dispos. 32(11), 1279-1286 (2004).
32. Park PW, Seo YH, Ahn JY, Kim KA, Park JYJ. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. Clin. Pharm. Ther. 34(5), 569-574 (2009).
33. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 95(1-2), 1-8 (2011).
34. Blanca Sánchez M, Herranz JL, Leno C et al. UGT2B7-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther. Drug Monit. 32(2), 177-184 (2010).
35. Chung JY, Cho JY, Yu KS et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther. 83(4), 595-600 (2008).
36. Rivers F, O'Brien TJ, Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur. J. Pharmacol. 598, 1-8 (2008).
37. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47, 1253-1284 (2006).
38. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48(Suppl. 5), 140-149 (2007); erratum in: Epilepsia 48, 2380 (2007).
39. Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55, 1364-1375 (2008).
40. Nicolas JM, Collart P, Gerin B et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 27(2), 250-254 (1999).
41. Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 47, 1818-1821 (2006).
42. Nakasa H, Nakamura H, Ono S et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol. 54, 177-183 (1998).
43. Sachdeo RC, Sachdeo SK, Levy R et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43(7), 691-696 (2002).
44. Li AP, Maural P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interactions 107, 5-16 (1997).
45. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm. 24, 475-490 (1996).
46. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann. Reb. Pharmacol. Toxicol. 38, 389-430 (1998).
47. Brown HS, Ito K, Galetin A, Houston JB. Predictions of in vivo drug-drug interactions from in vitro data: impact of incorporating parallell pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. 60(5), 508-518 (2005).
48. Brown HS, Galetin A, Halifax D, Houston JB. Predictions of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet. 45(10), 1035-1050 (2006).
49. Youdim KA, Zayed A, Dickins M et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as object of interaction. Br. J. Clin. Pharmacol. 65, 680-692 (2008).
50. McGinnity DF, Tucker J, Trigg S, Riley RI. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 33(11), 1700-1707 (2005).
51. Brown HS, Wilby AJ, Alder J, Houston JB. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab. Dispos. 38(12), 2139-2146 (2010).
52. Patsalos PN, Alavijeh MS, Semba J et al. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J. Pharmacol. Methods 28, 21-28 (1992).
53. Walker MC, Tong X, Perry H et al. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br. J. Pharmacol. 130, 242-248 (2000).
54. Hachad H, Ragueneau-Majlessi I, Levy RH. A useful tool for drug interactions evaluation: the University of Washington metabolism and transport drug interactions database. Hum. Genomics 5(1), 61-72 (2010).
55. Nunes T, Sicard E, Almeida L et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr. Med. Res. Opin. 26(6), 1335-1362 (2010).
56. Almeida L, Nunes T, Sicard E et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol. Scand. 121(4), 257-264 (2010).
57. Brodie MJ, Wilson EA, Wesche DL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine and vaproate is patients with partial epilepsy. Epilepsia 46(9), 1407-1413 (2005).
58. Sabers A, Buchholt JM, Uldall P et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 47, 151-154 (2001).
59. Sabers A, Öhman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61, 570-571 (2003).
60. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progesterone, reduces lamotrigine serum concentrations. Epilepsia 46(9), 1414-1417 (2005).
61. Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin. Pharmacol. Ther. 43, 372-375 (1988).
62. Parmeggiani A, Riva R, Posar A, Rossi PG. Possible interaction between acyclovir and antiepileptic treatment. Ther. Drug Monit. 17, 312-315 (1995).
63. Perucca E, Gidal BE, Baltés E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53(1-2), 47-56 (2003).
64. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49, 1123-1141 (2008).
65. Brodie MJ, Rosenfeld WE, Vazquez B et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 50, 1899-1909 (2009).
66. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 50(5), 1150-1157 (2009).
67. Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50, 443-453 (2009).
68. Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25(3), 347-363 (2003).
69. Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 49, 1239-1276 (2008).
70. Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs. J. Lab. Med. 35(3), 161-169 (2011).
71. Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol. Drug Saf. 128, 132-139 (2009).
72. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther. Drug Monit. 24, 366-374 (2002).
73. May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and comedication. Ther. Drug Monit. 25, 690-699 (2003).
74. May TW, Rambeck B, Neb R et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther. Drug Monit. 29, 789-794 (2007).
75. May TW, Boor R, Rambeck B et al. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther. Drug Monit. 33, 214-221 (2011).
76. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions. Epilepsy Res. 87, 31-39 (2009).
77. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997-2005-a study from The Netherlands. Eur. J. Clin. Pharmacol. 64, 1013-1020 (2008).
78. Ackers R, Besag FM, Wade A, Murray ML, Wong IC. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch. Dis. Child. 94(6), 443-447 (2009).
79. Hsia Y, Neubert A, Sturkenboom M et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 51(5), 789-796 (2010).
80. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch. Neurol. 62(9), 1432-1436 (2005).
81. Arif H, Svoronos A, Resor SR Jr, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability and efficacy. Epilepsia 52(10), 1905-1913 (2011).
82. Patsalos PN, Bourgeois BFD. The Epilepsy Prescriber's Guide to Antiepileptic Drugs. Cambridge University Press, Cambridge, UK (2010).
83. Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Disposit. 36, 36-45 (2008).
84. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92(2-3), 89-124 (2010).
85. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43(1), 11-58 (2001).